Dragonfly Expands Research Collaboration With AbbVie
April 20 2022 - 8:57AM
Dow Jones News
By Michael Dabaie
Dragonfly Therapeutics Inc. has expanded its research
collaboration with AbbVie for Dragonfly's immunotherapies for new
targets in autoimmune and fibrotic diseases.
Under the agreement, Dragonfly will grant AbbVie the option to
license exclusive worldwide intellectual property rights to
multiple new candidates developed using Dragonfly's TriNKET
technology platform. AbbVie will pay Dragonfly an upfront payment,
future milestone payments and royalties.
"We have seen strong progress in our current collaboration with
Dragonfly focused on their TriNKET technology and are pleased to
expand our partnership to include additional immunology targets of
interest to AbbVie," said Jonathon Sedgwick, vice president and
global head of discovery research at AbbVie.
AbbVie in January 2021 licensed its first TriNKET drug candidate
from Dragonfly, part of a multi-target collaboration initiated in
November 2019.
Write to Michael Dabaie at michael.dabaie@wsj.com
(END) Dow Jones Newswires
April 20, 2022 08:42 ET (12:42 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jun 2024 to Jul 2024
AbbVie (NYSE:ABBV)
Historical Stock Chart
From Jul 2023 to Jul 2024
